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Glycosyltransferasea b s t r a c t
Bordetella bronchiseptica produces respiratory disease primarily in mammals including humans. Although
a considerably amount of research has been generated regarding lipopolysaccharide (LPS) role during
infection and stimulating innate and adaptive immune response, mechanisms involved in LPS synthesis
are still unknown. In this context we searched in B. bronchiseptica genome for putative glycosyltrans-
ferases. We found possible genes codifying for enzymes involved in sugar substitution of the LPS struc-
ture. We decided to analyse BB3394 to BB3400 genes, closed to a previously described LPS biosynthetic
locus in B. pertussis. Particularly, conservation of BB3394 in sequenced B. bronchiseptica genomes suggests
the importance of this gene for bacteria normal physiology. Deletion of BB3394 abolished resistance to
naive serum as described for other LPS mutants. When purified LPS was analyzed, differences in the
LPS core structure were found. Particularly, a GalNA branched sugar substitution in the core was absent
in the LPS obtained from BB3394 deletion mutant. Absence of GalNA in core LPS alters immune response
in vivo but is able to induce protective response against B. bronchiseptica infection.
 2016 Published by Elsevier Ltd.Bacterial surface polysaccharides are known to contribute to
bacterium-host interaction, including symbiotic and pathogenic
relationships.1 Among these polysaccharides, the lipopolysaccha-
ride (LPS) is the major component of the outer membrane of
gram-negative bacteria and consists of highly variable as well as
conserved segments.2 In extremely small amounts LPS possess
potent bioactivities initiating the morbidity and mortality associ-
ated with Gram-negative sepsis as well as the modulation of a
myriad of host innate inflammatory responses. Interestingly, speci-
fic synthetic alterations within conserved segments of LPS were
shown to be recognized not only by host cells but were also cap-
able of blocking or down-regulating the response to other LPSforms normally associated with robust innate cell activation.3 In
fact, structural heterogeneity of LPS of certain pathogenic bacteria
like Helicobacter pylori, was shown to result in differential and
altered innate host cell responses.4–7
Bordetella bronchiseptica can infect a variety of mammals
including humans. Other authors and ourselves previously showed
that B. bronchiseptica expresses a LPS that plays an essential role in
host interaction, being critical for the early clearance of the bacte-
ria.8 Like in other pathogens, B. bronchiseptica isolates from human
patients presented LPS modifications.9 Purified B. bronchiseptica
LPS presents after electrophoresis in polyacrylamide gels a pattern
of three bands. Faster migrating band is called B and comprises a
lipid A domain and a branched-chain core oligosaccharide. Band
B is further modified by the addition of a complex trisaccharide
called band A (band B plus trisaccharide). In addition, a pentasac-
charide links the O antigen consisting in a homopolymer of 2,
3-dideoxy-2,3-di-N-acetylgalactosaminuronic acid to the core-
trisaccharide region.10 The complete structure, (band B plus band
A plus O antigen) is presented as the slower migrating band. Muta-
tion of genes involved in core synthesis usually abolish further LPS
synthesis.11,12 LPS structure in these mutants is called deep rough
because of mutant colony morphology and is visualized in
polyacrylamide gels as a single fast migrating band.
Fig. 1. LPS electrophoretic phenotype reveals modifications in BbDBB3398 but not
in BbDBB3394 mutant (A). Silver-stained SDS-PAGE 17.5% wt/vol profiles of phenol-
water-extracted LPS samples from Bb9.73H+ wild-type, BbDBB3394 mutant and
BbDBB3398 mutant strains. Both mutants showed different susceptibility to naïve
sera (B). 1000 CFU were exposed to naive sera at different proportions to SS
media. Appropriate dilutions were plate in BG after 2 h at 37 C. Results
are expressed as percentage of CFU recovered when were exposed to SS media.
⁄ indicates P < 0.05; Bb9.73H+ versus mutant.
Fig. 2. MALDI-MS spectrum of the B. bronchiseptica wild type 9.73H+ (A) and
BbDBB3394mutant (B) oligosaccharide in the reflectron positive ion mode using GA
as matrix.
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heptoses linked to lipid A. This composition is quite different from
other LPSs where up to three heptoses are present. Only three
genes, waaA, waaC and waaF are known to participate in the deep
core synthesis.11,12 Guerten and co-workers described in B. pertus-
sis four glycosyltransferases that participate in sugar core substitu-
tions. However, no effects in Bordetella pathogenesis has been
described for those mutants.13 We have previously reported that
a deep rough LPS mutant is unable to establish an infection in wild
type mice.12 Interestingly, we suggested that early elimination
may be the strong response to a deep rough LPS compared to
smooth LPS. Particularly an enhanced IL-12 and TNF-alpha
response was observed in mice treated with a deep rough LPS sug-
gesting that distal portions of LPS are involved in host immune
response regulation.12
We hypothesized that enzymes that catalyse the addition of
hexoses to the growing core of B. bronchiseptica LPS would be sim-
ilar to known glycosyltransferases from other bacteria. Therefore,
we found genes dispersed around all the B. bronchiseptica RB50
genome as shown in Supplemental Table S1. Pan-genome analysis
indicates that genes associated with diverse phenotypes, antibiotic
resistance or that confer selective advantages are often found
within the accessory genome rather than the core genome.14
Hester and co-workers suggested that horizontally acquired diver-
gent O-antigen contributes to escape from cross-immunity in the
classical Bordetellae.15 Dispersal position of these genes may sug-
gest a possible source of LPS structure diversity between different
Bordetella circulating strains. However, when other available gen-
omes were analyzed, those genes were in the same relative posi-
tion suggesting that glycosyltransferase genes are part of the
core rather than accessory genome. Some of those genes are
arranged in groups of putative glycosyltransferases. One of those
groups, involving BB3396 to BB3400 are homologous to BP2328 to
BP2331 previously described by Geurtsen and co-workers as glyco-
syltransferases involved in B. pertussis Tohama I LPS core synthe-
sis.13 Moreover, a similar group of genes in Burkholderia
cenocepacie were previously described.16 Interestingly, one of B.
cenocepacie genes, BCAL2407, a glycosyltransferase presents
homology to BB3394.
In order to confirm the role of this cluster of genes in LPS syn-
thesis, we constructed mutants in B. bronchiseptica 9.73H+ with
the individual genes BB3394 and BB3398 interrupted by an antibi-
otic resistance cassette. Wild type LPS presented a full length LPS
with defined bands A and B and a diffuse low moving band corre-
sponding to lipid A-core-O antigen structure. As expected,
BbDBB3398 LPS showed in Fig. 1A a fast moving unique band cor-
responding to a truncated LPS.
On the other hand, BbDBB3394 LPS profile was indistinguish-
able from wild type LPS suggesting that deletion of genes involved
in GlcN, GlcA or GalNA transfer to the core would not alter the
length of the LPS (Fig. 1A). As a first approach to evaluate possible
LPS modifications, sensitivity to naive serum were evaluated and
compared to wild type strain. Interestingly, BbDBB3394 and
BbDBB3398 did not grow properly in naive serum in contrast to
Bb9.73H+ strain. Resistance to both agents was restored when
BbDBB3394 mutant was complemented with the corresponding
gene. Results are shown in Fig. 1B.
To get deeper into the LPSs structures, LPSs from each mutant
strain were further purified. The corresponding oligosaccharides
were released by acid hydrolysis and analyzed by mass spectrom-
etry. The MALDI-MS spectrum of the B. bronchiseptica wild type
9.73H+ oligosaccharide in the reflectron positive ion mode using
GA as matrix is presented in Fig. 2A and supplemental Fig. S1. In
the high molecular weight range a signal at m/z 1637.0 (calc. m/z
1637.5537, C59H100N5O46Na) consistent with a core fragment con-
taining (Hep)GlcN-(GalNA)Glc-(GlcAGlcNHep)Hep bearing a FucNunit from the distal trisaccharide is present. Ion atm/z 1594.5 (calc.
m/z 1594.5353) would correspond to the loss of an acetyl group
from the latter. In accordance, ion at m/z 1456.1 (calc m/z 1456.
4319, C51H84N3Na2O42) would correspond to the core octasaccha-
ride fragment consistent with (Hep)GlcN-(GalNA)Glc-(GlcAGlcN-
Hep)Hep as an oxonium ion. In addition loss of the GalNA unit
from the latter gives rise to m/z 1259.7 (calc. m/z 1259.4019,
C45H76N2NaO37), and signal at m/z 1085.3 (calc. m/z 1084.3656,
C38H67N3NaO31) corresponds to the loss of GlcA and a Heptose unit
from m/z 1456.1. In addition, species at m/z 1191.1 (calc. m/z
1190.4059, C44H70N7Na2O29) is consistent with the distal trisaccha-
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GlcN-(GalNA)Glc.
The MALDI-MS spectrum of the mutant BB3394 strain oligosac-
charide in the positive ion mode (Fig. 2B and supplemental Fig. S2)
showed the highest mass species at m/z 1259.6 (calc. m/z
1260.4103, C45H77N2NaO37) and m/z 1281.6 (DNa) consistent with
the core fragment (Hep)GlcN-Glc-(GlcNGlcAHep)Hep. The lack of
higher m/z species would indicate the absence of the GalNA unit.
In addition, ion at m/z 1153.0 (calc. m/z 1153.3997, C42H72N3-
NaO32) is consistent with a FucN-(Hep)GlcN-Glc-Hep-Kdo core
fragment. Ions at m/z 1065.0 (calc. m/z 1064.2924, C35H61N3Na2-
O29P) and m/z 1021.0 (D44) correspond to FucN-GlcN-Glc-Hep-
KdoP fragment.
The MALDI-MS spectrum of the mutant BB3394 strain, per-
formed in the negative ion mode using nor-harmane as matrix
(Fig. 3A and supplemental Fig. S3) showed a complex pattern of
signals.
Ion at m/z 2281.2 (calc. m/z 2280.6719, C79H132N7O65P2) corre-
sponds to the core region consistent with (Hep)GlcN-Glc-
(GlcNGlcAHep)Hep-KdoPP linked to the Band A trisaccharide
GlcNAc-Man2,3NAcA-FucN. Ion at m/z 1706.9 (calc. m/z
1707.5860, C64H103N6O47) corresponds to Man2,3NAcA-
FucNGlcN-Glc(GlcNGlcAHep)Hep-anhKdo. Furthermore, loss of
the branching oligosaccharide constituted by (GlcN-GlcA)Hep and
a phosphate group from the latter renders ion at m/z 1130.6 (calc
m/z 1130.4104, C42H72N3O32 ). Signal at m/z 1840.1 (calc. m/z
1839.6312 C68H112N8O48P) would correspond to FucN linked to
the Band A trisaccharide plus (Hep)GlcN-Glc-Hep-anhKdoP. Ion
at m/z 1557.1 (calc. m/z 1557.6171, C60H101N8O39) may be due to
prompt fragmentation of m/z 1840.1, causing the loss of anhKdoP.
In addition, m/z 1272.2 (calc. m/z 1272.3325, C42H72N3O37P2) is
consistent with FucN-(Hep)GlcN-Glc-Hep-anhKdoPP. Furthermore,
ion at m/z 1993.7 (calc. m/z 1994.7606, C79H124N11O48) corre-
sponds to the fragment GlcNAc-Man2,3NAcA-FucN-GlcNAc-
Man2,3NAcA-FucN-GlcN-Glc-Hep-anhKdo-H2O; ion at m/z 2130.8Fig. 3. MALDI-MS spectrum of the mutant BbDBB3394 strain (A) and BbDBB3398
mutant (B) oligosaccharide performed in the negative ion mode.(calc. m/z 2131.6508, C74H125N8O59P2) would correspond to the
trisaccharide unit plus GlcN-Glc-(GlcAGlcNHep)Hep-Kdo-PPEA. In
the low MW range, main ion at m/z 842.9 (calc. m/z 843.2051,
C28H46NO26P) may be attributed to the (GlcN-Hep)Hep-anhKdoP
fragment. Interestingly no signals corresponding to fragments
bearing the GalNA unit could be detected. Conservation of
BB3394 in sequenced B. bronchiseptica genomes suggests the
importance of this substitution for bacteria normal physiology.
Resistance to naive sera is a phenotype usually modified when
LPS alterations are present. Long LPS structures avoid complement
components to reach bacterial surface. However in our hands, a
small modification like the absence of the branching GalNA was
sufficient to alter resistance to sera.
In several Bordetella LPS, a pentasaccharide fragment that links
the O-antigen to the core region has been identified.10 Previous
reports indicated that the O-chain of these bacteria LPS was a linear
homopolymer of 1,4-linked 2,3-dideoxy-2,3-diacetamido-L-galac-
turonic acid (L-Gal2,3NAcA).17 However, differences between the
end groups on B. bronchiseptica O antigens were described such as
the presence of a terminal residue (Lac-type, 328.3 Da, and
Ala-type, 327.3 Da). Further studies revealed that a proportion of
the O-polysaccharide repeating units are present as uronamide
(L-Gal2,3NAcAN), the number of which varies between strains.10
Also, the presence in the O-antigen of blocks of amides and blocks
of acids, whereas less abundant mixed amide/acid ions were
evidenced.
In accordance, signals related to the O-antigen oligosaccharide
were detected in the MALDI-MS spectrum of the mutant BB3394
strain. Thus, ion peak at m/z 2848.1 (calc. m/z 2848.0675,
C111H163N28O60) may be attributed to the O-antigen fragment built
up of a terminal ‘‘Lac type” residue, three uronamide units
(L-Gal2,3NAcAN), four 2,3-dideoxy-2,3-diacetamido-L-galacturonic
acids (L-Gal2,3NAcA) and three monosaccharides from the linking
pentasaccharide (Man2,3NAcAN-Glc2,3NAcAN-GalNAc) with the
concomitant loss of water. Ion at m/z 2583.1 (calc. m/z
2582.0044, C102H155N23O55) was assigned to a fragment built up
by two 2,3-dideoxy-2,3-diacetamido-L-galacturonic acids
(L-Gal2,3NAcA) and one uronamide unit (L-Gal2,3NAcAN) linked
to the pentasaccharide plus the Band A trisaccharide unit. Ion at
m/z 2418.4 (calc.m/z 2418.9663, C95H150N20O53) is consistent with
one uronamide unit linked to the pentasaccharide plus Band A
trisaccharide plus Hep-GlcN. In addition, ion at m/z 1418.3 (calc.
m/z 1418.5691, C56H86N14O29) is attributed to one uronamide unit
linked to the pentasaccharide and ion at m/z 1178.9 (calc. m/z
1178.4706, C46H72N11O25 ) corresponds to the pentasaccharide
unit.
In contrast, regarding mutant BB3398, the MALDI-MS spectrum
of the released oligosaccharide, in the negative mode (Fig. 3B and
supplemental Fig. S3) showed the highest mass ion at m/z 2287.9
(calc. m/z 2288.6883, C80H132N9O63P2) as expected for the lack of
the O-antigen structure suggested by SDS-PAGE. This ion corre-
sponds to a GlcNAc-Man2,3NAcA-FucN-GlcN-(GalNA)Glc-
(GlcNGlcAHep)Hep-anhKdoPPEtN structure. In addition, ion at m/
z 1997.6 (calc. m/z 1998.5667 C70H114N7O58P2) would correspond
to Man2,3NAcA-FucN-GlcN-(GalNA)Glc-(GlcN GlcAHep)Hep-
anhKdoPP after the loss of CO2 (44 l). Also ion at m/z 1561.1 (calc.
m/z 1561.4569, C54H90N4O46P) corresponds to FucN-GlcN-(GalNA)
Glc-(GlcAHep)Hep-KdoP. Furthermore, ions at m/z 1418.9 (calc. m/
z 1419.4800 C54H87N4O42) and m/z 1463.5 (D44) are ascribed to
FucN-GlcN-(GalNA)Glc-(GlcAHep)Hep-anhKdo. In all cases the
GalNA unit linked to the Glc of the core region was present in this
mutant.
Interestingly, absence of GalNA in BB3394 mutant is not detri-
mental for distal structures synthesis. However, absence of lateral
Heptose in BB3398 LPS generated a rough LPS indicating that Hep-
tose needs to be present to be recognize as a substrate for enzymes
Fig. 4. Effect of systemic (i.p.) immunization with different LPS structures and
challenged with wild type Bb9.73H+ in C3H/HeN (black columns) or C3H/HeJ mice
(grey columns). Statistical analysis was performed by ANOVA and Tukey test.
⁄ indicate significant differences with p < 0.001 respect to C3H/HeN mice.
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reported with core second heptose.11 Deletion ofwaaF an heptosyl-
transferase involved in second heptose addition generated a deep
rough phenotype.
Once confirmed we have B. bronchiseptica LPS with deep modi-
fications (deep rough LPS from BbLP39 and BbDBB3398) or mildly
modifications like BbDBB3394 we hypothesized that structural dif-
ferences will held different immune responses. We have previously
shown that a deep rough LPS triggers different interleukine
responses in bone marrow derived dendritic cells.18
Dendritic cell response to smooth or complete B. bronchiseptica
LPS is characterized by high TNF-alpha levels. Same response is
observed when wild type LPS is instilled in naïve mice.19 Hence
we evaluate if LPSs first described in the present work were able
to elicit a TNF-alpha response. When LPS derived from BB3398 or
BB3394 mutants were intranasally instilled in mice, differences
were observed (Table 1).
Interestingly, deep rough LPS derived from BbDBB3398 elicited
non significantly differences to wild type LPS. However, we showed
that GalNA substitution is important to induce TNF-alpha
response. Absence of this lateral sugar in B. bronchiseptica LPS inhi-
bits TNF-alpha response (Table 1). Interestingly, TNF-alpha is an
important factor secreted during first steps of infection and its
absence is detrimental to limitation of B. bronchiseptica infection.19
It has been suggested that LPS immune activity may be respon-
sible for directing an appropriated protective response.20,21 There-
fore, a previously tested vaccination schedule was used to evaluate
protection capacity of the different LPSs here in described.22
Female three weeks old BALB/c mice were i.p. immunized with
5 lg of purified wild type LPS. As a control, whole cell formalde-
hyde inactivated vaccine was used to immunize mice. After 2
immunizations, mice were challenged intranasally with sublethal
doses of wild type B. bronchiseptica. Five days after challenge, ani-
mals were sacrificed and the number of bacteria in lungs was
determinate. As expected not immunized mice presented a high
number in CFU/lung, while whole cell immunized mice were pro-
tected against infection progress (Fig. 4).
One of main components of whole cell vaccine is LPS. When
mice were immunized with B. bronchiseptica wild type LPS no sig-
nificantly differences were observed with mice immunized by
whole cell (Fig. 4).
Protection induced by B. bronchiseptica LPS was genera and spe-
cies specific. If we immunized with either B. pertussis or E. coli
DH5a LPS, no protection was observed (Fig. 4). Both E. coli DH5a
and B. pertussis LPS are short-chain LPS, commonly named
lipooligosaccharide. Interestingly B. pertussis and B. bronchiseptica
core structure showed no differences.
When mice were immunized with 5 lg of a deep rough LPS
from BbLP39 mutant no protection was observed supporting that
distal LPS portions are necessary to induce protection (Fig. 4).
Using the same vaccination and challenge schedule, purified LPS
from BbDBB3398 and BbDBB3394 with confirmed structure
changes were evaluated. As shown in Fig. 4, BbDBB3398 deep
rough LPS was not able to elicit a protective response in mice as
the other deep rough LPS from BbLP39. Interestingly, LPS from
BbDBB3394 mutant, lacking the GalNA unit in the core, protects
mice against infection as the wild type LPS. This result is in agree-Table 1
Relative expression report generated by REST2009 after 2000 iterations.24 Values are obtain
9.73H+ LPS stimulated mice. P(H1): Probability of alternate hypothesis that difference bet
TNF-alpha expression Std
LPS BbDBB3398 0.556 0.2
LPS BbDBB3394 0.242 0.1ment to Buboltz and co-workers report. They showed that modifi-
cations in distal structures on O-antigen are sufficient to induce
different protective responses.23 Hence, even somehow core LPS
structure can modify immune response, distal portions of LPS like
O-antigen are necessary and sufficient to trigger a protective
response. These results should be considered to develop a vaccine
with cross protection between Bordetella species.
In conclusion, we have identified a new gene involved in the
synthesis of the core LPS in B. bronchiseptica. Genes involved in dis-
tal LPS structure synthesis have been described previously. How-
ever, genes involved in core synthesis remains unknown
probably due to dispersal location of genes through the genome.
The core is a branched hetero-oligomer. Function of core lateral
sugars are unknown. Here we presented first steps in function
description, using LPS mutants with different core modifications.
We also demonstrated that LPS modifications correlates with
reduction in resistance to naive sera. In addition, differences in
immune response to LPS were observed, however lateral modifica-
tion GalNA was expendable to elicit protection against B. bron-
chiseptica infection. Further research is needed to establish role
of all sugars present in Bordetella LPS. This knowledge will be nec-
essary to design LPS containing vaccines.Conflict of interest
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